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Abstract
To investigate the effect of increasing dietary polyunsaturated fat intake on fat absorption in Crohn’s patients, normal
subjects and subjects with inactive Crohn’s disease consumed a high polyunsaturated to saturated fat ratio diet. Subjects
 .participated in breath tests before and after six months of a high polyunsaturated to saturated PrS fat ratio diet to measure
w 13 x w 13 xtheir response to 1- C 10:0 and 1- C 16:0 ingested with a test meal. Whole body absorption-oxidation of C10:0 was not
affected by the diet treatment. Before diet treatment, whole body absorption-oxidation of C16:0 in Crohn’s patients was
80% of that observed for control subjects. After consuming a high polyunsaturated to saturated fatty acid ratio diet, subjects
 .increased oxidation of C16:0 by 85% compared to before the diet treatment period. It is concluded that 1 absorption of
 .labelled C16:0 from a test meal is reduced in Crohn’s patients, and 2 consumption of a high polyunsaturated to saturated
fatty acid ratio diet improves the utilization of dietary C16:0 by Crohn’s patients.
Keywords: Crohn’s disease; Diet; Fat absorption
Abbreviations: APE, atom percent excess; CDAI, Crohn’s
disease activity index; CIU, Clinical Investigation Unit of the
University of Alberta Hospitals; PrS, polyunsaturated to satu-
rated.
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1. Introduction
Altering dietary fat intake modifies membrane
structure, function and molecular control mechanisms
w xin animals fed nutritionally complete diets 1,2 . For
example, intestinal absorption of fatty acid and
cholesterol can be altered by diet fat-induced changes
w xin membrane composition 3 . Feeding streptozo-
tocin-diabetic rats diets high in polyunsaturated fats
normalizes the jejunal and ileal uptake of palmitic
 .  . w xacid 16:0 and oleic acid 18:1 4 . Dietary fat
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intake also prevents development of acetic acid-in-
w xduced colitis in rats 5 . Animals fed high polyunsatu-
rated fat diets treated with acetic acid to induce
colitis were found to decrease colonic fluid secretion
and increase ileal fluid absorption compared to ani-
mals fed a diet high in saturated fat. Together these
observations suggest that changes in diet fat alter the
mechanisms involved in regulating physiological up-
take of fatty acids into the enterocyte.
Membrane fatty acids have important roles in in-
flammatory cell function as well as the inflammatory
response. Metabolites of 20:4-n6 released from phos-
w xpholipid 6–8 , exert a wide variety of biological
effects, including chemotaxis, vascular permeability,
muscle contraction, platelet aggregation and media-
tion of inflammatory response. Since altering dietary
polyunsaturated fat composition changes membrane
w xphospholipid 20:4n-6 content 1 , it is logical to
expect that transitions in diet fat that alter the
metabolism of 20:4n-6 or 20:5n-3 may also alter the
inflammatory process.
As dietary fat modifies enterocyte composition and
transport of fatty acid in the small bowel in animals,
we wished to determine if making analogous changes
in the human diet would improve fat absorption in
persons with Crohn’s disease. Crohn’s disease is a
chronic inflammatory process of unknown etiology
w x9–12 . The inflamed mucosa presents with decreased
w x18:2n-6 and 20:4n-6 content 13 . Abnormal plasma
polyunsaturated fatty acid is also a characteristic of
w xnon-active inflammatory bowel disease 14 . The in-
flammatory process is typically patchy with diseased
areas separated by lengths of normal bowel. The
intestinal damage which occurs may result in de-
creased nutrient absorption and increased fecal losses.
In Crohn’s disease, corticosteroids and sulfasala-
zine are most commonly prescribed as anti-inflamma-
tory agents and are thought to specifically inhibit
prostaglandin biosynthesis by the cyclo-oxygenase
w xpathway 15–18 . Sulfasalazine also blocks produc-
 .tion of leukotrienes lipoxygenase pathway , particu-
larly leukotriene B and certain hydroxy- fatty acids4
that are potent chemotactic agents in the local recruit-
ment of inflammatory cells into inflammation sites
w x19 . Since both pathways of 20:4n-6 metabolism are
blocked by metabolites of sulfasalazine and 5-
aminosalicylic acid, the exact mode of pharmacologic
action is uncertain. Eicosanoids are also important in
w xthe pathogenesis of diarrheal diseases 20 . It is possi-
ble that prostaglandins, after being synthesized in the
subepithelium, may regulate ion and water transport
by acting on the epithelium. Prostaglandins elevate
cAMP levels in vivo by a receptor-mediated mecha-
w xnism 21 that stimulates adenylate cyclase on the
basolateral membrane of epithelial cells, supporting
the possibility that prostaglandins have a physio-
logical role in control of mucosal transport. Uncon-
trolled formation of eicosanoids may be the source of
diarrhea associated with mucosal inflammation and
may also be critical to the inflammatory response.
Eicosapentaenoic acid inhibits both the cyclo-
oxygenase and the lipoxygenase products of 20:4n-6
and may play an important role in restoring altered
prostaglandins resulting from the inflammatory pro-
w xcess in Crohn’s disease 20 . In patients with inflam-
matory bowel disease, dietary fish oil supplementa-
tion improved rectal dialysate leukotriene B levels4
and histological parameters compared to placebo sup-
plementation while reducing the effective dose of
w xprednisone 22 .
Feeding a diet high in polyunsaturated fat pro-
 .  .motes transport of palmitic 16:0 stearic 18:0 and
 .oleic 18:1 acid at specific sites in the brush border
w xmembrane of normal rats 23,24 , however, uptake of
medium-chain fatty acids is unaffected. In diabetic
animals increased intestinal uptake of carbohydrates
and lipids is observed, but this can be normalized by
w xfeeding a diet high in polyunsaturated fat 24,25 .
These experiments suggest that manipulation of di-
etary lipid may influence important intestinal func-
tions including transport processes and transporter
activity.
The present study was designed to determine if
consumption of a high polyunsaturated to saturated
fat diet by Crohn’s patients would affect the whole
body absorption-oxidation of long-chain fatty acids
and improve the tolerance to fat in the diet. Breath
tests, previously used to determine absorption-oxida-
w xtion rates for dietary fatty acids in humans 26,27
were utilized.
2. Methods
Procedures used in this study were approved by
the Ethics Committee of the Faculty of Medicine,
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Table 1
Nutrient composition per 100 g reconstituted supplement
aNutrient High PrS supplement
 .  .  .  .Total g kcal CHO g Protein g Fat g
Skim milk 62.5 21.8 3.1 2.2 0
Dry skim milk powder 5.85 21.2 3.0 2.1 0
Sugar 7.01 27.0 7.0 0 0
Maltodextrin 7.5 28.9 7.5 0 0
Soya protein 2.4 9.6 0 2.2 0.2
Beatreme 14.5 98.9 2.4 0.68 9.5
Lecithin 0.12 – – – –
Vitamin mix 0.1 – – – –
Flavouring 0.05 – – – –
Total energy of the supplements was 2.1 calrg.
a The high PrS supplement was analyzed to be 42% fat, 44% carbohydrate and 14% protein as energy.
 .The fatty acid composition of the high PrS supplement was: 12:0, 0.93%; 14:0, 0.37%; 16:0, 12.9%; 16:1 7 , 0.13%; 18:0, 2.55%;
 .  .  .  .18:1 9 , 24.89%; 18:1 7 , 0.56%; 18:2 6 , 55.44%; 18:3 3 , 0.93%; 20:0, 0.34%.
University of Alberta. All subjects gave informed,
written consent.
2.1. Protocol
Patients with Crohn’s disease were recruited from
cases presenting at the University of Alberta Hospi-
tals. Thirteen subjects in clinical remission with a
CDAI of less than 150 were prescreened by a 3-day
food record. Those subjects who normally consumed
 .a higher PrS ratio )0.9 in their dietary fats were
selected to obtain six subjects having a higher PrS
intake. The remaining seven subjects initially pre-
screened exhibited a lower PrS intake. Subjects re-
ceived dietary counselling throughout the study pe-
riod by the research dietician to ensure that their
dietary fat composition remained in the high PrS
range. By regular contact with the subject, the dieti-
cian evaluated dietary compliance and assessed the
usage of a dietary supplement consumed throughout
the study. Subjects who completed the study were
required to ingest the high polyunsaturated fat sup-
 .plement Table 1 without interruption for a 6 month
period. Failure to tolerate the supplement for 6 months
resulted in dropping the subject from the study.
Entry and follow-up visits were conducted on an
out-patient basis at 1.5, 3 and 6 months. Upon entry
to the study, each subject completed a questionnaire
which included: personal and medical history, dietary
habits, anthropometric measurements, assessment of
Table 2
Clinical profile of Crohn’s subjects at study entry who participated in the final breath tests a
aSubject % Ideal Site Bowel Dietary PrSAssociated medical problems
bbody wt. resection ratio groupCurrent Past
c1 96 sb no – – high
c2 85 sbqcolon no joint pain fistula high
c3 112 sb no – – high
4 100 colon no – fissure high
a Dietary PrSspolyunsaturated fatty acid to saturated fatty acid ratio on entry to study was high PrS)0.9.
b Based on Metropolitan Life Table, 1983 standards.
c Patient completed study.
Sitessite of Crohn’s; sbssmall bowel.
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CDAI, smoking and alcohol habits and family history
 .of inflammatory bowel disease Table 2 . Prior to
each follow-up visit, a 3-day food record was com-
pleted and blood and stool samples were collected
w x28 . Standard medical management was maintained
throughout the study.
Healthy free-living adult males were recruited as
control subjects. Four control subjects were instructed
to consume three or four servings of the high PrS
supplement per day depending on their weight and
activity level, in addition to their normal diet and
w 13 xtheir response to 1- C palmitic acid measured. To
w 13 xcompare the response to 1- C decanoic acid for
patients with Crohn’s disease with that of normal
subjects, six normal subjects were fed a diet of
normal foods providing a PrS ratio of 1.0 i.e.
.similar to the diet intake of Crohn’s patients , 40%
calories as fat, and a constant intake of C10:0rC16:0
for 6 days before giving breath samples.
2.2. De˝elopment of the high PrS supplement
The often unpleasant taste of many commercially
available enteral supplements does not enable contin-
ual consumption. Such supplements do not contain
the fatty acid composition appropriate for this study.
Our goal was to ensure that the type of fat consumed
was high in polyunsaturated fat and to develop a
palatable supplement to ensure subject compliance.
The supplement was nutritionally complete and con-
tained high amounts of polyunsaturated fat so that
when combined with the subject’s normal diet, the
supplement would significantly influence the overall
 .dietary polyunsaturatedrsaturated fat PrS ratio. For
example, a female subject consuming two servings
 .400 ml of high PrS supplement per day along with
1200 kcal from her regular diet with a PrS ratio of
0.25 would still have an overall dietary PrS ratio of
0.95, ensuring a high PrS intake for each study day.
By adjusting the amount of supplement to the sub-
ject’s total estimated energy requirement the dietary
PrS ratio could be consistently maintained at these
levels.
The powdered supplement was developed and pro-
duced at the Food Processing Development Centre
 .Leduc, ALTA . The powdered form was preferred,
as fresh milk could be added just before consump-
tion. The canned ready-to-use product is less econom-
ical and the flavour is often less acceptable. Fat used
in the supplement, encapsulated corn oil, was ob-
 .tained from Beatrice Food Ingredients Beloit, WI .
Beatreme-3618. Fats were encapsulated with sodium
caseinate and corn syrup solids to improve the disper-
sal and emulsion when shaken with fresh milk. Vanilla
and banana flavoured supplements were prepared.
The serving size was 75 g of dry powder shaken with
125 ml of skim milk. The nutrient composition of the
supplement when reconstituted with milk is illus-
 .trated Table 1 . The supplement had a PrS ratio of
3.2 as determined by fatty acid analysis. Fat extrac-
tion was carried out on homogenized samples of the
w xreconstituted supplement 29 prior to saponification
and transesterification with KOH and boron trifluo-
w xride methanol reagent 30 . Fatty acid methyl esters
were analyzed by gas-liquid chromatography Varian,
.Georgetown, Ontario and identified by comparison
of retention data with authentic standards. The energy
value of the supplement was determined by bomb
 .calorimetry Parr Instruments, Moline, IL to be 2.1
calrg. The fatty acid composition of the reconstituted
 .supplement is shown Table 1 .
Subjects were provided with the supplement in the
dry powdered form with a 200-ml scoop, to give the
 .appropriate serving size 75 g . Subjects kept a con-
tainer of powdered supplement in the freezer and a
1-week supply in the refrigerator for immediate use.
For one serving, 125 ml of skim milk was added to
200 ml powder and shaken until mixed. Subjects
were instructed to consume the supplement 2–4
timesrday, depending on their body weight. To as-
sess subject acceptance of the supplement and poten-
tial for non-compliance, taste panels were performed
using normal individuals and subjects with Crohn’s
disease. Both subject groups found the supplement at
least as acceptable as a commonly used commercially
available supplement.
2.3. Breath collection
Study participants were admitted to the Clinical
 .Investigation Unit CIU of the Walter Mackenzie
Health Sciences Centre on an out-patient basis. Six
subjects with Crohn’s disease completed breath tests
before receiving the nutritional supplement.
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Each subject spent 3 days providing breath collec-
tion for breath tests before andror after the 6 month
study period. Each subject was tested with labelled
decanoic and palmitic acids. At least 48 h elapsed
between isotope feeding days to allow for clearance
of 13C. Complete stools were collected for 3 days,
starting on each isotope feeding day. Each subject
reported to the CIU at 0730 h. The subject consumed
a test meal which was identical for breakfast and
lunch. Each meal was formulated to provide 20% of
the subjects’ estimated daily energy requirement. Test
meals were formulated to be 45% calories as carbo-
hydrate, 15% calories as protein and 40% calories as
fat with a PrS ratio of 0.3. The food content of the
 .meal is illustrated Table 3 . On the first breath
collection day, food without added label was con-
sumed to permit examination of the 13C content of
respiratory CO from metabolism of the test meals2
w x w 13 xalone 26 . On subsequent test days either 1- C de-
w 13 xcanoic or 1- C palmitic acid was ingested in cap-
sule form with the breakfast meal. The order of
ingestion of each labelled fatty acid was systemati-
cally randomized. The 13C-enriched fatty acids were
obtained from MSD Isotopes Merck-Frosst Canada,
.Montreal, QC and assessed for isotopic and chemical
purity in our laboratory. Palmitic acid was )99%
w 13 xchemically pure and contained 99.5 atom% 1- C .
Decanoic acid was also )99% chemically pure and
w 13 xcontained 95.2 atom% 1- C . The labels were fed at
a level based on prior analysis of chemical and
isotopic purity of the fatty acids at a dose of 20 mg
w 13 x w 13 x1- C 16:0 per kg body wt. and 3 mg 1- C 10:0
Table 3
Food composition of test meal
ag kcal
Corn flakes 28.7 106
2% milk 196.0 97
60% whole wheat bread 74.3 183
Pork sausage 91.2 332
Becel margarine 6.8 50
Butter 6.8 54
Orange juice 398.6 178
Total 1000
a  .The fat content of the test meal was gr1000 calories : 10:0,
 .  .  .0.4; 16:0, 12.1; 18:0, 5.2; 18:1 9 , 18.8; 18:2 6 , 4.3; 18:3 3 ,
 .  .0.4; 20:3, 0.2; 20:4 6 , 0.1; 20:5 3 , 0.1.
per kg body wt. to provide a dose of 1.0 and 0.25 mg
13C per kg body wt., respectively.
Hourly breath samples were collected from the
reclining subject for 6 min between 0730 h and 1630
h on the test days. The subject breathed through a
mouthpiece and Rudolph valve Roxon Medi-Tech
.Ltd., Montreal, QC into a 100-l Latex bag. After
breath collection, the bag was evacuated at 0.5 lrmin
through a 100-cm spiral trap containing 10 ml of 1 N
NaOH. The respiratory sample was bubbled through
the NaOH solution for 3 min, trapping all CO . The2
resulting solution was transferred to a 50-ml tube
along with several rinses with distilled water. Sam-
ples were frozen at y308C until analyzed. The re-
maining respiratory gases were evacuated at 9 lrmin.
The flow rates were monitored with flow meters
 .Fischer and Porter, Warminster, PA and flow times
were recorded. Respiratory CO was regenerated un-2
der vacuum by mixing 1.0 ml of the NaOH solution
 .with 0.6 ml phosphoric acid 85% wrv in a Ritten-
burg tube. The tube was maintained at 258C until the
 .reaction was complete approx. 20 min. and attached
to the mass spectrometer. The total weight of CO2
exhaled into the bag during 6 min. was estimated by
adding excess 1 M BaCl to the NaOHrHCO solu-2 3
tion from the spiral trap to precipitate BaCO and3
using gravimetric techniques.
2.4. Mass spectrometry
13CO abundance analysis was performed using a2
dual inlet Isotope Ratio Mass Spectrometer Finnigan
. 13MAT 251, Bremen, Germany . C abundances were
corrected for 17O and pressure drift according to
w x 13Mook and Grootes 31 . Multiple C abundance
 .analyses ns6 of CO liberated from NBS a202
limestone standard demonstrated the analytical preci-
 .sion CV of the instrument at 0.0036%. The CV of
 .replicate determinations ns12 was 0.0069% for
purified CO from combusted unlabelled palmitic2
acid. The mass spectrometer has a twelve sample
automatic multiport system. An acetonerliquid nitro-
gen bath was inserted between the multiport and the
inlet system of the mass spectrometer to condense
water vapour in the sample. Duplicate analyses were
performed for each breath sample collected against a
reference CO tank standard. Results were expressed2
as d 13C per ml vs. PDB standard which were con-
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13  .verted to atom percent CO AP . Background AP2
values were then subtracted from each time-point on
a day when 13C-labelled substrate was fed to yield
 .atom % excess APE due to the absorption-oxidation
of the substrate only. Values at the initial time point
for each substrate test day were used as the zero
reference point. Subsequent points were adjusted ac-
cordingly and used to compare profiles based on
similar intakes of 13C.
2.5. Statistics
Means were compared where possible by Students
w xt-test 32 . Data were analyzed using repeated mea-
sure analysis of variance with whole plot sources of
variation of diet, subjects within diet and repeated
measures of time. Comparisons of diet means within
time were made using least significant difference
 .LSD with error degree of freedom using the
Huynh-Feldt adjustment.
3. Results
Over the 6 month treatment period a mean de-
crease in body weight of 1.3"0.7% was observed
for the four subjects with Crohn’s disease. Individual
weight changes over the treatment period ranged
from y2.7 to q0.2 kg. Blood samples were col-
lected on admission to the study and at 1 and 1.5, 3
and 6 months. Complete blood counts were measured
at all four visits. Complete chemical profiles includ-
ing nutritional parameters were assessed at the begin-
ning and end of the study. No significant change in
these routine clinical tests was found between these
test results over the 6 month period.
Due to the 3-day time commitment necessary to
complete breath tests in each treatment period, sub-
jects were asked to participate in pre-, post- or both
test periods. Two subjects agreed to participate only
in the post-treatment breath tests.
Study dropouts occurred due to an inability to
consistently tolerate the supplement and maintain a
constant diet fat intake. Symptoms of intolerance
consisted of diarrhea, nausea, bloating and abdominal
pain. When subjects reported intolerance to the sup-
plement, it was suggested that they abstain from
using the supplement until the symptoms disappeared
and then gradually re-introduce the supplement by
using half-servings. In all cases the adverse symp-
toms reappeared and these subjects withdrew from
the study. Two subjects consuming the supplement
reported intolerance.
Two subjects decreased their CDAI scores over the
6 month treatment period. The CDAI score for the
 .other subject was unchanged. The mean "S.E.M.
decrease in CDAI was 30"17% of that measured
before treatment for this group. Since the patients
with Crohn’s disease were already in remission, a
30% decrease in CDAI scores is unlikely to be of
clinical significance.
 .Mean "S.E.M. total fat excretion in the stool
decreased from 38"15 mmolrday before diet treat-
ment to 10"2 mmolrday after consuming the sup-
 .plement normal range is 0–20 mmolrday . The total
fat intake, calculated from the food records, increased
for the Crohn’s subjects who completed the study.
These Crohn’s subjects increased their fat intake by
an average of 8.8"2.1%. Since these subjects in-
creased their fat intake but at the same time de-
creased the fecal fat, the efficiency of fat absorption
improved.
w 13 x 13After oral intake of 1- C decanoic acid, C was
detected in breath CO within 1 h and peaked after2
 .four to 5 h Fig. 1a . No significant difference was
observed between the pooled excess 13C excreted per
h in the breath before or after taking the supplement.
w 13 xThe average percentage of the original dose of 1- C
10:0 oxidized over 9 h was 54"4% before the
supplement period and 53"6% after the study pe-
w 13 xriod. The amount of 1- C 10:0 oxidized was simi-
 .lar to that observed for six normal subjects Fig. 1 .
w 13 x 13Following ingestion of 1- C 16:0, C enrich-
 .ment appeared in breath CO after about 3 h Fig. 2a2
and peaked after 6–7 h. The amount of 13C due to
absorption-oxidation of the substrate increased signif-
icantly from the start of the study period after con-
suming the supplement. The average percentage
 ."S.E.M. of the fatty acid excreted in breath CO2
increased from 4.4"1.1% before the treatment pe-
riod to 7.6"1.1% after treatment. Before the treat-
ment period, the area under the breath 13CO excre-2
tion curve over the 9 h examination period for sub-
jects with Crohn’s disease was only 80% of that for
the control group of normal subjects. After consum-
ing the supplement, the Crohn’s subjects increased
( )M.A. French et al.rBiochimica et Biophysica Acta 1360 1997 262–270268
the area under the curve by 85% over that observed
before the treatment period. For most sample times
there was no significant difference between the ab-
 .  . 13Fig. 1. A Mean "S.E.M. mmol C excreted in breath CO2
w 13 xafter oral administration of 1- C decanoic acid after subtraction
of background 13C levels. Responses are shown for subjects with
 .Crohn’s disease before treatment B-B, ns4 , after 6 month
 .diet treatment with high PrS supplement I-I, ns4 , and for
 .normal subjects consuming a high PrS diet v-v, ns6 . No
 .significant difference was found between the three groups. B
Area under the curve over the 9 h test day for the different diet
treatments when 10:0 was the labelled substrate. No significant
difference was found between control and before diet treatment
or before and after the diet treatment.
 .  . 13Fig. 2. A Mean "S.E.M. mmol C excreted in breath CO2
w 13 xafter oral administration of 1- C palmitic acid after subtraction
of background 13C levels. Responses are shown for subjects with
 .Crohn’s disease before treatment B-B, ns4 , after 6 month
 .diet treatment with high PrS supplement I-I, ns4 and for
normal subjects consuming a high fat, high PrS diet v-v,
.ns4 . Significant differences were found before and after diet
)  .supplementation with the high PrS supplement. P -0.05. B
Area under the curve over the 9 h test day for the different diet
treatments when 16:0 was the labelled substrate. Significant
 .difference P -0.05 was found between the high PrS diet
treatment group and before the treatment period.
sorption-oxidation rates of subjects with Crohn’s dis-
ease after the treatment period and control subjects.
For both substrates, the response peaked approxi-
mately 1 h earlier after the diet treatment than before
the treatment.
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4. Discussion
The palmitic acid absorption-oxidation observed
for the Crohn’s patients increased from 4.4"1.1%
before the treatment period to 7.6"1.1% after treat-
ment. This compares favourably with Watkins et al.
w x33 who found that 2.1"1.5% of the administered
dose of palmitic acid was excreted in breath over 6 h
for patients with mucosal disorders compared to 6.6
"2.4% for normal subjects. These authors have
w 13 xsuggested that breath tests using 1- C palmitic acid
may be useful in diagnosing the etiology of certain
types of steatorrhea i.e. pancreatic insufficiency vs.
.mucosal disease .
Several studies of dietary management of Crohn’s
w xdisease have investigated fat restriction 34 , fibre
w x w xrestriction 35 , increased unrefined carbohydrate 36 ,
w x w xelimination 37 and elemental 38 diets. A study by
w xAndersson et al. 34 investigated patients with
Crohn’s disease, most of whom had been subjected to
ileal resection, and compared the effect of a low fat
 .  .40 grday versus a high fat 100 grday diet. The
general condition of the patients improved when con-
suming the low fat diet, including diarrhea, steator-
rhea and electrolyte balance. Weight gain was ob-
served even though the fat intake was significantly
reduced from the mean 150 g reported in home use.
The fatty acid composition of the test diets were not
shown, but a predominance of polyunsaturated fat in
the low fat diet was mentioned. It is possible that the
improved status of the subjects could have been due
not so much to the amount of dietary fat, but to the
increased amount of polyunsaturated fat consumed in
the low fat diet.
The eicosanoids PGE and LTB are abnormally2 4
w xhigh in Crohn’s patients 20 . A study using normal
subjects consuming different dietary fat levels and
PrS ratios measured LTB and LTB levels after4 5
stabilization on the diet and also after fish oil supple-
w xmentation of the diet 39 . Fish oil supplementation
decreased LTB for subjects consuming three out of4
the four diet treatments. LTB levels increased in the4
low fat, high PrS diet. Fish oil supplementation
raised LTB levels with all diets. The beneficial5
effect of fish oil supplementation of patients with
Crohn’s disease is controversial. Esteve-Comas et al.
w x40 measured plasma fatty acids in patients with
Crohn’s disease and control subjects. From their data
the plasma fatty acid n-6rn-3 ratio for normal sub-
jects was 25, whereas for Crohn’s patients the n-6rn-
3 ratio was only 8.6. Thus, feeding Crohn’s patients
n-3 fatty acids such as fish oil would only reduce this
ratio further from normal levels. The n-6rn-3 ratio of
our high PrS supplement was 60, which would aid in
increasing plasma fatty acid n-6rn-3 ratio toward the
normal value. Dietary n-6rn-3 ratio seems to play an
important role in the observation of beneficial effects
of PUFAs in the diet, not merely the PrS ratio.
w 13 xWhen the labelled substrate ingested was 1- C
10:0, no significant difference was observed between
normal subjects and subjects before and after taking
the supplement. Crohn’s disease does not appear to
affect the absorption of medium-chain fatty acids.
w 13 xBecause the absorption-oxidation of 1- C 10:0 was
not affected by the diet treatment, it is also unlikely
that the diet treatment altered gastric emptying rate
for the test meal used. However, when the diets of
subjects with Crohn’s disease were supplemented
with a high PrS supplement, the mean whole body
w 13 xabsorption-oxidation of 1- C 16:0 nearly doubled
and was close to that of control subjects. It is con-
cluded that absorption of long-chain fatty acids from
a test meal is lower for subjects with Crohn’s disease
compared to normal subjects, and that diminished
whole body absorption-oxidation of long-chain fatty
acids for this small group of Crohn’s patients can be
normalized by consumption of a high polyunsaturated
diet fat. These results are analogous to diet-induced
changes in absorption reported earlier for an animal
w xmodel 4 .
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